Skip to main content

Advertisement

Table 1 Clinical characteristics at the first study visit in 435 children in the Nordic juvenile idiopathic arthritis (JIA) cohort according to the presence of acute or chronic uveitis during > 7 years of follow-up

From: Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study

  All children No uveitis Acute uveitis Chronic uveitis
N   N   N   N  
Female gender 435 286 (65.8) 346 227 (65.6) 9 4 (44.4) 80 55 (68.8)
Age at onset, median (1st, 3rd q) 435 5.5 (2.4, 9.5) 346 6.2 (2.8, 10) 9 10.8 (9.3, 12.9) 80 3.2 (1.8, 5.9)
Oligoarticular onseta 435 224 (51.5) 346 180 (52.0) 9 1 (11.1) 80 43 (53.8)
ANA positive 427 116 (27.2) 340 79 (23.2) 9 0 (0) 78 37 (47.4)
AHA >15 U/ml 134 23 (17.2) 112 14 (12.5) 3 1 (33.3) 19 8 (42.1)
RF positive 424 10 (2.4) 336 9 (2.7) 9 1 (11.1) 79 0 (0.0)
HLA-B27 positive 413 87 (21.1) 325 62 (19.1) 9 7 (77.8) 79 18 (22.8)
ESR, median (1st, 3rd q) 354 14 (8, 28) 276 14 (8, 26) 8 23 (10, 41) 70 16 (9, 36)
CRP, median (1st, 3rd q) 350 0 (0, 10) 276 0 (0, 10) 9 0 (0, 16) 65 0 (0, 14)
JADAS27, median (1st, 3rd q) 194 5.1 (2.0, 11.0) 157 5.0 (2.0, 9.8) 7 10.4 (5.6, 14.9) 30 3.8 (1.6, 12.5)
CHAQ, median (1st, 3rd q)) 273 0.3 (0.0, 1.0) 222 0.4 (0.0, 1.0) 8 0.4 (0.1, 1.2) 43 0.3 (0.0, 1.0)
DMARD use 2nd visitb 350 125 (35.6) 316 111 (35.1) 7 3 (37.5) 27 11 (42.3)
  1. Data are presented as numbers (%), unless otherwise noted
  2. ANA antinuclear antibodies measured by immunofluorescence on Hep-2 cells, and RF rheumatoid factor; two positive tests taken > 3 months apart in participants with one or more tests taken, AHA > 15 U/ml antihistone antibodies IgM/IgG >15 U/ml, HLA-B27 human leucocyte antigen B27, Age at onset age at onset of arthritis in years, ESR erythrocyte sedimentation rate, CRP C-reactive protein JADAS27 Juvenile arthritis disease activity score based on 27 joint count, CHAQ Child health assessment questionnaire
  3. aOligoarticular JIA 6 months after disease onset, according to the International League of Associations for Rheumatology (ILAR) classification criteria. [25]
  4. bPercentage of DMARD = Disease modifying anti-rheumatic drugs including biological agents used within the 2nd visit (median 13 months (IQR 12–14)) in 350 children without uveitis at the time of the 2nd study visit, differentiating into no uveitis, acute, or chronic uveitis during further follow-up